Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"),...
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"),...
SALT LAKE CITY, Aug. 2, 2023 /PRNewswire/ -- Matia Mobility, a leading provider of innovative mobility solutions, today announced the...
MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States,...
Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging...
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia...
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of...
Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low...
Achieving the standard of care, no matter the language or disability.ANN ARBOR, MI / ACCESSWIRE / July 19, 2023 /...
Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE®GENEVA, SWITZERLAND / ACCESSWIRE /...
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled...
Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced...
Company adds seasoned MedTech CFO to leadership teamMARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...
Data will be presented from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human...
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Data were presented to demonstrate that DPM-1003 provides a mechanism-based approach to the treatment of Rett Syndrome and is poised...
MINNEAPOLIS, June 15, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death...
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...
MS Canada’s cycling fundraising event series is back this June featuring road bike tours across 12 Canadian communities, bringing people...